Extended-release sodium oxybate for spasmodic dysphonia and voice tremor
Tests sodium oxybate on voice symptoms in people with spasmodic dysphonia.
Key facts
- Who runs it
- Kristina Simonyan
- Where
- Boston, United StatesSee the site
- Trial code
- Registry title
- Extended-release Sodium Oxybate (Lumryz) in Spasmodic Dysphonia and Voice Tremor
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 8 people, planned
- Started
- 1 Oct 2026
- Expected to end
- 30 Sept 2027
- Type of study
- Interventional
- Treatments tested
- sodium oxybate
- Record updated
- 28 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with laryngeal dystonia (spasmodic dysphonia) that improves with alcohol, who responded well to Xyrem before. It tests the extended-release drug sodium oxybate (Lumryz) on voice symptoms.
- Age
- 21 to 80 years
- Sex
- Men and women
- Disease stage
- A documented diagnosis of laryngeal dystonia whose symptoms improve with alcohol. Voice tremor alongside it is allowed.
- Earlier treatment
- Must have had a documented good response to immediate-release sodium oxybate (Xyrem) in earlier studies. People treated with botulinum toxin must have full symptoms again and be at least 3 months past the last injection.
Main reasons for not taking part
- Pregnancy or breastfeeding
- Grade 2 or higher liver or kidney problems, or moderate to severe heart failure
- Memory or thinking problems (MoCA < 26), past or present suicidal thoughts, or other psychiatric or neurological disorders
- Alcoholism, high risk of alcohol use problems, drug dependence, strong daytime sleepiness (ESS>10), or current use of medicines that act on the brain
- Past brain or voice box surgery, or metal objects or tattoos that make an MRI scan unsafe
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and lifestyle considerations (see Lifestyle Considerations below) and availability for the duration of the study
- Males and females
- Age 21-80 years
- Documented diagnosis of alcohol-responsive laryngeal dystonia
- Documented positive response to immediate-release sodium oxybate (Xyrem) in prior studies
- Willingness to adhere to the study intervention regimen
Who cannot take part
- Current use of medication(s) affecting the central nervous system
- Moderate to severe congestive heart failure
- Cognitive impairment (MoCA < 26)
- Alcoholism or high risk for alcohol use disorder according to the NIAAA definition and DSM-5 criteria
- Past or present history of any neurological disorders (except for LD and co-occurring voice tremor), such as stroke, movement disorders, brain tumors, traumatic brain injury with loss of consciousness, ataxias, myopathies, myasthenia gravis, demyelinating diseases, alcoholism, drug dependence
- Past or present history of any psychiatric problems, such as schizophrenia, major and/or bipolar depression, or obsessive-compulsive disorder
- Past or present history of brain and/or laryngeal surgery
- Presence of certain tattoos, ferromagnetic objects in their bodies (e.g., implanted stimulators, surgical clips, prosthesis, artificial heart valve, etc.) that are not MRI comparable and/or cannot be removed for the purpose of MRI study participation
- The incapability of giving informed consent
- Pregnancy or breastfeeding until a time when they are no longer pregnant or breastfeeding
- Grade 2 or higher hepatic or renal dysfunction according to the NCI criteria
- Past or present suicidal ideations (according to C-SSRS)
- Asymptomatic presentation due to botulinum toxin treatment until the time they are fully symptomatic and are at least 3 months after the last injection
- Increased daytime sleepiness (Epworth Sleepiness Scale (ESS>10))
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 80 years old?
Where in United States
- Massachusetts Eye and EarBoston, United StatesContact: Kristina Simonyan, MD, PhD, DrMedNot yet recruiting
About the trial
What the trial wants to find out
Using a comprehensive approach of clinico-behavioral testing and neuroimaging, the researchers will examine the clinical effects of the extended-release formulation of sodium oxybate on voice symptoms in spasmodic dysphonia in an open-label, proof-of-concept, dose-finding study.
The group in the trial
- Clinical response to sodium oxybate (Lumryz)Treatment being tested
Oral administration of sodium oxybate (1.5g, 2.0g, 2.5g, 3.0g)
Treatment: sodium oxybate
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Central Mechanisms and Treatment Response of Sodium Oxybate (Lumryz) in Spasmodic Dysphonia and Voice Tremor
- Plain-language title
- Extended-release sodium oxybate for spasmodic dysphonia and voice tremorGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT07041203, who can take part
- Record updated
- 28 April 2026